Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsors and Collaborators: |
University of California, San Francisco National Institutes of Health (NIH) |
---|---|
Information provided by: | University of California, San Francisco |
ClinicalTrials.gov Identifier: | NCT00505427 |
The study will recruit 40 subjects with Polycystic Ovary Syndrome (PCOS) as defined by the NIH criteria. The subjects will be pre-screened for insulin sensitivity using fasting insulin and glucose levels and oral glucose tolerance test. The 20 most insulin resistant subjects will undergo measurements of in vivo insulin action by hyperinsulinemic, euglycemic clamp. Body composition will be measured by dual-energy X-ray absorptiometry (DEXA).
Plasma lipids and markers of oxidative stress will be measured. They will then receive open label controlled release alpha lipoic acid (CRLA) at 800 mg twice daily for 16 weeks. After treatment hyperinsulinemic euglycemic clamps, DEXA, plasma lipids and markers of oxidative stress will be repeated. Hypotheses: LA will improve insulin sensitivity in PCOS subjects; LA will reduce oxidative stress, testosterone levels and improve cardiovascular risk factors.
Condition | Intervention | Phase |
---|---|---|
Insulin Resistance Oxidative Stress |
Dietary Supplement: Alpha Lipoic Acid |
Phase I |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Single Group Assignment, Efficacy Study |
Official Title: | Alpha Lipoic Acid and Polycystic Ovary Syndrome |
Estimated Enrollment: | 20 |
Study Start Date: | March 2006 |
Estimated Study Completion Date: | June 2008 |
Estimated Primary Completion Date: | June 2008 (Final data collection date for primary outcome measure) |
Insulin resistance commonly occurs in patients with Polycystic Ovary Syndrome (PCOS) and may be responsible for many of the long term complications of PCOS. Patients with PCOS are at increased risk for developing type 2 diabetes and the metabolic syndrome (hypertension, dyslipidemia and cardiovascular disease). Data suggest that oxidative stress contributes to insulin resistance and thus inhibitors of oxidative stress improve insulin action. Alpha Lipoic Acid (LA) is synthesized in the liver and other tissues and is a key component of several mitochondrial enzyme complexes responsible for oxidative glucose metabolism and cellular energy production. When used pharmacologically, LA functions as a safe and effective antioxidant, recycling vitamins C and E,elevating glutathione levels,and lowering reactive oxygen species. Cell culture studies reveal that LA reverses the effects of oxidative stress and improving insulin action. Preliminary clinical data indicate that antioxidants may improve insulin resistance in PCOS patients. We propose, therefore, to study LA's effects on insulin-stimulated glucose uptake (insulin clamp) in a well characterized population of insulin resistant PCOS patients. Because these patients usually present in the adolescent and teenage years, the development of safe, long-term, treatment strategies are needed.
Ages Eligible for Study: | 18 Years to 50 Years |
Genders Eligible for Study: | Female |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
United States, California | |
University of California at San Francisco | |
San Francisco, California, United States, 94143 |
Principal Investigator: | Umesh Masharani, MD | University of California, San Francisco |
Principal Investigator: | Ira Goldfine, MD | University of California, San Francisco |
Study ID Numbers: | 8476-27691-01 |
Study First Received: | July 20, 2007 |
Last Updated: | June 11, 2008 |
ClinicalTrials.gov Identifier: | NCT00505427 History of Changes |
Health Authority: | United States: Institutional Review Board |
PCOS polycystic ovary syndrome polycystic ovarian syndrome |
alpha lipoic acid insulin resistance oxidative stress |
Antioxidants Vitamin B Complex Metabolic Diseases Gonadal Disorders Alpha-lipoic Acid Stress Endocrine System Diseases Trace Elements Ovarian Diseases Cysts Insulin Polycystic Ovarian Syndrome |
Genital Diseases, Female Hyperinsulinism Vitamins Polycystic Ovary Syndrome Micronutrients Endocrinopathy Insulin Resistance Glucose Metabolism Disorders Metabolic Disorder Ovarian Cysts Thioctic Acid |
Antioxidants Molecular Mechanisms of Pharmacological Action Gonadal Disorders Physiological Effects of Drugs Ovarian Diseases Genital Diseases, Female Hyperinsulinism Pathologic Processes Syndrome Vitamins Micronutrients Metabolic Diseases Disease |
Vitamin B Complex Growth Substances Endocrine System Diseases Cysts Protective Agents Pharmacologic Actions Adnexal Diseases Neoplasms Polycystic Ovary Syndrome Insulin Resistance Glucose Metabolism Disorders Ovarian Cysts Thioctic Acid |